Monthly COVID-19 death rates per 100,000 population stratified by age group, race/ethnicity, sex, and region

Overall Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United States at national level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities. 

Count and percent of total COVID-19 deaths since January 1, 2020, by age group, race/ethnicity, and sex

This site provides historical data related to COVID-19 booster dose eligibility presented on two CDC COVID Data Tracker sites: Vaccinations in the US and Vaccination Equity.  Data are updated weekly on Thursdays.

Some COVID-19 vaccine recipients are eligible to receive booster doses,  and criteria for booster eligibility may change over time. Data and footnotes will be updated to align with the current recommendations.  

CDC counts people as having “received a booster dose” if they are fully vaccinated and received another dose of any COVID-19 vaccine on or after August 13, 2021. This does not distinguish whether the recipient is immunocompromised and received an additional dose

Data Limitations: 

• The booster eligibility metric excludes fully vaccinated recipients who have an “Other” primary series vaccine type.  
• Booster eligibility counts and percentages exclude vaccine administrations reported by Texas as the primary series cannot be linked to booster dose in the aggregate data submitted by Texas. 

Footnotes:

CDC counts people as being “eligible to get a booster dose<

This site provides historical data beginning June 22, 2022, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States” site titled “Primary Series Completion, Booster Dose Eligibility, and Booster Dose Receipt by Age, United States”.

Fully Vaccinated / Completed Primary Series:

• For surveillance purposes, COVID Data Tracker counts people as being "fully vaccinated" or as having "completed a primary series" if they received two doses on different days (regardless of time interval) of the two-dose mRNA series or received one dose of a single-dose vaccine. When the vaccine manufacturer is not reported, the recipient is considered fully vaccinated with two doses.

First Booster Dose: 

• For surveillance purposes, the count and percentage of people who received a first booster dose includes anyone who is fully vaccinated and has received another dose of COVID-19 vaccine since August 13, 2021. This includes people who received a first booster dose and people who received an additional primary series dose as this metric does not distinguish if the recipient is  immunocompromised and received an additional dose.
• First booster dose eligibility:
  • CDC counts people as being " eligible for a first booster dose" if it has been at least 5 months since completion of a Pfizer-BioNTech or Moderna primary series or at least 2 months since receipt of a Janssen (Johnson & Johnson) singe-dose vaccine.

Second Booster Dose:

• For surveillance purposes, the count and percentage of people who received a second booster dose includes anyone who is fully vaccinated and has received two subsequent doses of COVID-19 vaccine since August 13, 2021. This includes people who received two booster doses and people who received one additional dose and one booster dose. 
• The count of people who received a second booster dose and the percentage of people with a first booster who received a second booster dose does not account for whether a person is immunocompromised or time interval since first booster dose.
• Second booster dose eligibility:
  • CDC counts people as being  "eligible for a second booster dose"  if it has been at least 4 months since receiving a first booster dose.
• Limitations to counting people with a second booster dose:
  
  • Due to the aggregate vaccination record reporting method used by Idaho for its residents under the age of 18 years and by Texas for all its residents, CDC counts all 4th doses received by these populations as a second booster dose. This includes immunocompromised individuals who received a three-dose primary series and only one booster dose. This limitation may lead to an undercount of people who received the single-dose J&J/Janssen vaccine as their primary series and two booster doses.
  
  

Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

This site provides data for select demographic characteristics (age, sex, and age by sex) of people receiving COVID-19 vaccinations in the United States at the national and jurisdictional levels. For national race/ethnicity data, please visit COVID-19 Vaccination Demographics in the United States,National. For jurisdictional race/ethnicity data, please visit the relevant health department website if available.

Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities. 

Explore the Current Cigarette Smoking Among Adults Infographic which outlines key facts related to current smoking among adults. For accessibility issues contact OSHData@cdc.gov.

2011-2019. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. BRFSS Survey Data. The BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. The data for the STATE System were extracted from the annual BRFSS surveys from participating states. Tobacco topics included are cigarette and e-cigarette use prevalence by demographics, cigarette and e-cigarette use frequency, and quit attempts. NOTE: these data are not to be compared with BRFSS data collected 2010 and prior, as the methodologies were changed. Please refer to the FAQs / Methodology sections for more details.

2013-2014. The National Adult Tobacco Survey (NATS) was created to assess the prevalence of tobacco use, as well as the factors promoting and impeding tobacco use among adults. NATS also establishes a comprehensive framework for evaluating both the national and state-specific tobacco control programs. NATS was designed as a stratified, national, landline, and cell phone survey of non-institutionalized adults aged 18 years and older residing in the 50 states or D.C. It was developed to yield data representative and comparable at both national and state levels. The sample design also aims to provide national estimates for subgroups defined by gender, age, and race/ethnicity.

1996-2010. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. BRFSS Survey Data. The BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. The data for the STATE System were extracted from the annual BRFSS surveys from participating states. Tobacco topics included are cigarette smoking status, cigarette smoking prevalence by demographics, cigarette smoking frequency, and quit attempts. NOTE: these data are not to be compared with BRFSS data collected 2011 and forward, as the methodologies were changed. Please refer to the FAQs / Methodology sections for more details.